Company Analysis
Sign in

Ocular Therapeutix, Inc. (OCUL)

Nasdaq: OCUL · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.2
◀ Past 6.4● Present 4.3▶ Future 5.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

18 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ocular Therapeutix, Inc.’s names, not what it holds today.

Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 5 in 2024 and 3 in 2023
Applications published
40
11 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
Medical technology6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
OCULAR THERAPEUTIX, INC. its own name
named as the applicant on its applications, in US
0 granted
40 published
OCULAR THERAPEUTIX, INC. its own name
US, as the owner printed on each patent
18 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,453,724Ocular implant containing a tyrosine kinase inhibitorPharmaceuticalsOCULAR THERAPEUTIX, INC.
Jul 15, 202512,357,565Ocular implant containing a tyrosine kinase inhibitorPharmaceuticalsOCULAR THERAPEUTIX, INC.
Jun 17, 202512,329,853Compositions and methods for treating ocular diseasesPharmaceuticalsOCULAR THERAPEUTIX, INC.
May 27, 202512,310,890Punctal plug and bioadhesivesMedical technologyOCULAR THERAPEUTIX, INC.
Feb 18, 202512,226,341Implant injector deviceMedical technologyOCULAR THERAPEUTIX, INC.
Dec 10, 202412,161,753Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agentPharmaceuticalsOCULAR THERAPEUTIX, INC.
Nov 26, 202412,150,896Punctal plug and bioadhesivesMedical technologyOCULAR THERAPEUTIX, INC.
Nov 19, 202412,144,889Methods of treating allergic conjunctivitisPharmaceuticalsOCULAR THERAPEUTIX, INC.
Oct 8, 202412,109,302Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporinePharmaceuticalsOCULAR THERAPEUTIX, INC.
Jul 2, 202412,023,276Intracanalicular depot inserter deviceMedical technologyOCULAR THERAPEUTIX, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0332094OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITORPharmaceuticalsOCULAR THERAPEUTIX, INC.
Aug 28, 20252025/0268818COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASESPharmaceuticalsOCULAR THERAPEUTIX, INC.
Aug 28, 20252025/0268750PUNCTAL PLUG AND BIOADHESIVESMedical technologyOCULAR THERAPEUTIX, INC.
Jul 24, 20252025/0235438OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITORIPharmaceuticalsOCULAR THERAPEUTIX, INC. · patent 12,453,724 granted from it
Jul 10, 20252025/0221848IMPLANT INJECTOR DEVICEMedical technologyOCULAR THERAPEUTIX, INC.
Apr 17, 20252025/0120906SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENTPharmaceuticalsOCULAR THERAPEUTIX, INC.
Apr 10, 20252025/0114373INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENTPharmaceuticalsOCULAR THERAPEUTIX, INC.
Apr 3, 20252025/0108003METHODS OF TREATING ALLERGIC CONJUNCTIVITISPharmaceuticalsOCULAR THERAPEUTIX, INC.
Mar 20, 20252025/0092013PRODRUGS OF AXITINIBPharmaceuticalsOCULAR THERAPEUTIX, INC.
Feb 27, 20252025/0064760INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENTPharmaceuticalsOCULAR THERAPEUTIX, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Medical technology 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OCUL · research, not advice